BioLargo at $0.08: Has the Selling Finally Reached Capitulation?

​

At just $0.08 a share, BioLargo may be approaching the kind of extreme technical condition from which explosive microcap reversals can emerge.

​

There are moments in the life of a stock when the chart becomes so negative, sentiment becomes so pessimistic, and selling becomes so intense that the very forces driving the decline can eventually create the conditions for a reversal.

​

BioLargo, Inc. (OTCQX: BLGO) may be approaching such a moment.

​

The shares have now fallen to approximately $0.08, an extraordinarily depressed level compared with where the stock traded earlier this year. The question for investors is no longer simply whether BLGO has been weak.

​

It obviously has.

​

The far more interesting question is:

​

Could the stock now be entering a climactic selling phase—and could an equally dramatic reversal follow?

​

The $0.08 Level Changes the Technical Picture

​

When a stock falls from substantially higher levels to just eight cents, something important happens psychologically.

​

Most of the investors who were going to sell because of fear, frustration or disappointment have already had enormous incentive to do so.

At $0.08, the potential reward for selling another few cents lower becomes progressively smaller, while the potential percentage gain from even a modest rebound becomes enormous.

​

Consider the mathematics.

​

From $0.08:

• A move to $0.10 represents a 25% gain.

• A move to $0.12 represents a 50% gain.

• A move to $0.16 represents a 100% gain.

• A move to $0.20 represents a 150% gain.

• A move to $0.24 represents a 200% gain.

 

That asymmetry is precisely why extremely beaten-down microcaps can become explosive when sentiment suddenly changes.

​

The stock does not need to return immediately to its previous highs.

​

It simply needs buyers.

​

The Importance of a Climactic Selloff

​

One of the most closely watched patterns in technical analysis is the selling climax.

​

A selling climax occurs when investors who have been holding through a prolonged decline finally capitulate. Volume can surge as large numbers of shares change hands, sometimes producing a final downward acceleration.

​

Importantly, high volume by itself does not prove a bottom.

​

But when exceptionally heavy volume occurs near an extreme low after a prolonged decline, technical analysts begin watching closely for evidence that sellers may be exhausting themselves.

​

That is the potential significance of what is happening with BLGO.​

​

The stock is now trading around $0.08—well below the approximately $0.11 level where BioLargo’s CEO received restricted stock awards in June and July. Those shares were subject to a milestone-based lock-up, so they were not simply immediately available for sale.

The lock-up is tied to BioLargo reaching either $40 million in consolidated gross revenue or a $300 million market capitalization, absent a change in control. Both are roughly 10× milestones from today’s scale: $40 million represents about a tenfold step-up from the company’s current revenue base, while a $300 million market cap would equate to a share price around $0.80, or roughly 10× the current ~$0.08 share price.

​

The market is therefore reaching a price level where the question of who remains willing to sell becomes increasingly important.

​

A Reversal Could Be Violent

​

Microcap stocks do not always reverse gradually.

​

When liquidity is limited, a relatively modest amount of new buying can move the price substantially.

​

Imagine BLGO stabilizes at $0.08.

​

Then buyers begin appearing at $0.08 and $0.081.

​

The stock moves to $0.09.

​

A 12.5% move suddenly attracts attention.

​

Then $0.10.

​

Now the stock is up 25% from the bottom.

​

Momentum traders notice.

​

Existing shareholders become more confident.

​

Investors who sold at $0.08 begin wondering whether they sold too early.

​

Then technical traders see the first higher high and higher low.

​

Suddenly, the psychology of the stock has changed.

​

Fear can turn into FOMO extraordinarily quickly in a stock trading at eight cents.

​

That is why the next several trading sessions could be much more important than the preceding several months.

​

The Fundamental Story Has Not Vanished

​

The technical setup becomes even more intriguing because BioLargo continues to pursue multiple commercial opportunities.

In its August 17 update, BioLargo reported that second-quarter revenue increased 12% sequentially and that gross margin expanded to 54%. Management also highlighted continued progress at Clyra Medical and plans for an October relaunch of its consumer-products business under a company-owned model.

​

BioLargo's environmental technology also continues to generate commercial validation. Its AEC PFAS-remediation system at Lake Stockholm, New Jersey, had treated more than two million gallons of contaminated water while consistently reducing PFAS to levels below applicable New Jersey standards.

​

Those developments do not guarantee that BLGO will rise.

​

But they do provide something critically important to a technical reversal:

​

a fundamental story that can potentially produce catalysts.

​

If commercial progress accelerates while the stock is sitting at $0.08, the disconnect between market sentiment and business developments could become increasingly important.

​

What Would Confirm the Bull Case?The next signal is not complicated.Watch price and volume.

​

The strongest bullish confirmation would be:

​

First: BLGO holds the $0.08 area rather than establishing materially lower lows.

​

Second: selling volume begins to diminish.

​

Third: the stock starts producing higher intraday lows.

​

Fourth: BLGO moves back through $0.09 and $0.10.

​

Fifth: volume expands dramatically as the stock advances.

​

That final point is critical.

​

A price increase on insignificant volume can easily fail.

​

A price increase accompanied by a major expansion in volume is much more interesting because it indicates that buyers are becoming increasingly aggressive.

​

A sustained move above $0.10 could therefore become an important psychological and technical event.

​

The Contrarian Opportunity

​

The market is currently treating BLGO as though the company's problems are far more important than its potential.

That may ultimately prove correct.

​

But markets frequently overshoot in both directions.

​

At $0.08, BioLargo's stock price has already experienced an extraordinary degree of pessimism. The company is still operating, still developing commercial technologies, still reporting revenue, and still pursuing growth opportunities.

​

The stock therefore presents a classic contrarian question:

​

What happens if the company merely stops getting worse?

​

And an even more interesting question:

​

What happens if something actually goes right?

​

At $0.08, even relatively modest positive developments could have a dramatic percentage impact on the stock.

​

That is the essence of the current technical setup.

​

Bottom Line

​

BioLargo at $0.08 is undeniably a high-risk speculative situation.

​

But precisely because the stock has been beaten down so severely, it may also be approaching a potentially powerful technical inflection point.

​

The combination of an extreme price decline, apparent capitulation-type selling, exceptionally depressed valuation sentiment, and continuing corporate developments creates the possibility of a violent countertrend rally if buyers finally take control.

​

The key is not predicting the exact bottom.

​

The key is watching for evidence that the bottom may already have occurred.

​

If BLGO can hold the $0.08 area, reverse higher and attract substantially heavier buying volume, the resulting move could be surprisingly large.

​

At eight cents, BioLargo no longer needs a small improvement to produce a meaningful percentage move. It needs only a change in market psychology.

 

And after a climactic selloff, that change can sometimes happen with astonishing speed.

​

The stock has been crushed. The question now is whether the selling has finally run its course—and whether BLGO is setting up for the kind of explosive reversal that few investors expect when sentiment is at its darkest.

​

This article represents a bullish technical-analysis perspective and is not investment advice or a guarantee of future performance. BLGO is a highly speculative microcap security and investors should consider the substantial risks, including volatility, liquidity, financing, dilution, execution and the possibility of further losses.

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.

​